Search or filter publications

Filter by type:

Filter by publication type

Filter by year:

to

Results

  • Showing results for:
  • Reset all filters

Search results

  • Journal article
    Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Staehle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MKB, Oza AMet al., 2011,

    A Phase 3 Trial of Bevacizumab in Ovarian Cancer

    , NEW ENGLAND JOURNAL OF MEDICINE, Vol: 365, Pages: 2484-2496, ISSN: 0028-4793
  • Journal article
    Tulah AS, Parker SG, Moffatt MF, Wardlaw AJ, Connolly MJ, Sayers Iet al., 2011,

    The role of <i>ALOX5AP</i>, <i>LTA4H</i> and <i>LTB4R</i> polymorphisms in determining baseline lung function and COPD susceptibility in UK smokers

    , BMC MEDICAL GENETICS, Vol: 12
    • Cite
    • Citations: 12
  • Journal article
    Paternoster L, Standl M, Chen CM, Ramasamy A, Bonnelykke K, Duijts L, Ferreira MA, Alves AC, Thyssen JP, Albrecht E, Baurecht H, Feenstra B, Sleiman PM, Hysi P, Warrington NM, Curjuric I, Myhre R, Curtin JA, Groen-Blokhuis MM, Kerkhof M, Saaf A, Franke A, Ellinghaus D, Folster-Holst R, Dermitzakis E, Montgomery SB, Prokisch H, Heim K, Hartikainen AL, Pouta A, Pekkanen J, Blakemore AI, Buxton JL, Kaakinen M, Duffy DL, Madden PA, Heath AC, Montgomery GW, Thompson PJ, Matheson MC, Le Souef P, St Pourcain B, Smith GD, Henderson J, Kemp JP, Timpson NJ, Deloukas P, Ring SM, Wichmann HE, Muller-Nurasyid M, Novak N, Klopp N, Rodriguez E, McArdle W, Linneberg A, Menne T, Nohr EA, Hofman A, Uitterlinden AG, van Duijn CM, Rivadeneira F, de Jongste JC, van der Valk RJ, Wjst M, Jogi R, Geller F, Boyd HA, Murray JC, Kim C, Mentch F, March M, Mangino M, Spector TD, Bataille V, Pennell CE, Holt PG, Sly P, Tiesler CM, Thiering E, Illig T, Imboden M, Nystad W, Simpson A, Hottenga JJ, Postma D, Koppelman GH, Smit HA, Soderhall C, Chawes B, Kreiner-Moller E, Bisgaard H, Melen E, Boomsma DI, Custovic A, Jacobsson B, Probst-Hensch NM, Palmer LJ, Glass D, Hakonarson H, Melbye Met al., 2011,

    Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis

    , Nature Genetics, Vol: 44, Pages: 187-192, ISSN: 1546-1718

    Atopic dermatitis (AD) is a commonly occurring chronic skin disease with high heritability. Apart from filaggrin (FLG), the genes influencing atopic dermatitis are largely unknown. We conducted a genome-wide association meta-analysis of 5,606 affected individuals and 20,565 controls from 16 population-based cohorts and then examined the ten most strongly associated new susceptibility loci in an additional 5,419 affected individuals and 19,833 controls from 14 studies. Three SNPs reached genome-wide significance in the discovery and replication cohorts combined, including rs479844 upstream of OVOL1 (odds ratio (OR) = 0.88, P = 1.1 x 10(-13)) and rs2164983 near ACTL9 (OR = 1.16, P = 7.1 x 10(-9)), both of which are near genes that have been implicated in epidermal proliferation and differentiation, as well as rs2897442 in KIF3A within the cytokine cluster at 5q31.1 (OR = 1.11, P = 3.8 x 10(-8)). We also replicated association with the FLG locus and with two recently identified association signals at 11q13.5 (rs7927894; P = 0.008) and 20q13.33 (rs6010620; P = 0.002). Our results underline the importance of both epidermal barrier function and immune dysregulation in atopic dermatitis pathogenesis.
  • Journal article
    Barnard A, Posocco P, Pricl S, Calderon M, Haag R, Hwang ME, Shum VWT, Pack DW, Smith DKet al., 2011,

    Degradable Self-Assembling Dendrons for Gene Delivery: Experimental and Theoretical Insights into the Barriers to Cellular Uptake

    , JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, Vol: 133, Pages: 20288-20300, ISSN: 0002-7863
  • Journal article
    MacCallum RM, Redmond SN, Christophides GK, 2011,

    An expression map for <i>Anopheles gambiae</i>

    , BMC GENOMICS, Vol: 12, ISSN: 1471-2164
  • Journal article
    Xia M, Guerra N, Sukhova GK, Yang K, Miller CK, Shi G-P, Raulet DH, Xiong Net al., 2011,

    Immune Activation Resulting From NKG2D/Ligand Interaction Promotes Atherosclerosis

    , CIRCULATION, Vol: 124, Pages: 2933-U419, ISSN: 0009-7322
    • Cite
    • Citations: 43
  • Journal article
    Anand PK, Tait SWG, Lamkanfi M, Amer AO, Nunez G, Pages G, Pouyssegur J, McGargill MA, Green DR, Kanneganti T-Det al., 2011,

    TLR2 and RIP2 Pathways Mediate Autophagy of <i>Listeria monocytogenes</i> via Extracellular Signal-regulated Kinase (ERK) Activation

    , JOURNAL OF BIOLOGICAL CHEMISTRY, Vol: 286, Pages: 42981-42991
  • Journal article
    Jackson A, Watson V, Back D, Khoo S, Liptrott N, Egan D, Gedela K, Higgs C, Abbas R, Gazzard B, Boffito Met al., 2011,

    Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.

    , J Acquir Immune Defic Syndr, Vol: 58, Pages: 450-457

    OBJECTIVES: To investigate the pharmacokinetics of darunavir/ritonavir and raltegravir, in HIV-infected subjects, in both plasma and at the intracellular (IC) site of action. METHODS: HIV-infected patients on antiretroviral therapy received raltegravir 400 mg twice daily for 21 days (period 1); darunavir/ritonavir 800/100 mg once daily was added for 14 days (period 2), and patients were randomized to continue raltegravir twice daily (group 1) or to switch to 800 mg once daily (group 2), then they all stopped raltegravir intake and continued darunavir/ritonavir once daily for 14 days (period 3). Drug concentrations in plasma and cells (peripheral blood mononuclear cell) were measured, and differences in geometric mean ratios (GMR) and 90% confidence intervals (CI) between period 2 versus period 3 and period 2 versus period 1 were assessed. RESULTS: Twenty-four patients completed the study. Group 1 GMR (90% CI) of darunavir area under the curve (AUC) with and without raltegravir was 1.24 (1.13 to 1.45) for plasma and 1.24 (1.07 to 1.73) for cells and for group 2 was 1.14 (1.07 to 1.24) and 1.03 (0.94 to 1.16). GMR (90% CI) of raltegravir AUC without and with darunavir/ritonavir (plasma and cells) for group 1 was 0.90 (0.73 to 1.44) and 1.02 (0.81 to 1.67) and for group 2 was 1.21 (1.03 to 1.77) and 1.27 (1.07 to 1.94). Geometric mean IC to plasma AUC ratios were 5.3 and 4.9 for darunavir in groups 1 and 2 when darunavir/ritonavir was given alone and 4.9 and 5.6 for raltegravir when given alone. These ratios were not altered by the coadministered drug. CONCLUSIONS: No remarkable interactions between darunavir/ritonavir and raltegravir in plasma or cells were seen. Raltegravir IC concentrations are higher than previously reported; the difference being due to modified cell isolation procedures that reduced drug loss caused by washing.
  • Journal article
    Gupta A, Sjoukes A, Richards D, Banya W, Hawrylowicz C, Bush A, Saglani Set al., 2011,

    Relationship between Serum Vitamin D, Disease Severity, and Airway Remodeling in Children with Asthma

    , AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 184, Pages: 1342-1349, ISSN: 1073-449X
    • Cite
    • Citations: 251
  • Journal article
    Balkwill FR, Coward J, Kulbe H, Milagre C, Gopinathan G, McNeish IAet al., 2011,

    IL-6 and Ovarian Cancer-Response

    , CLINICAL CANCER RESEARCH, Vol: 17, Pages: 7838-7838, ISSN: 1078-0432

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://www.imperial.ac.uk:80/respub/WEB-INF/jsp/search-t4-html.jsp Request URI: /respub/WEB-INF/jsp/search-t4-html.jsp Query String: id=1208&limit=10&resgrpMemberPubs=true&page=1419&resgrpMemberPubs=true&respub-action=search.html Current Millis: 1778449420881 Current Time: Sun May 10 22:43:40 BST 2026